Aktieanalys

Xspray Pharma: Additional positive XS003 data - Redeye

{newsItem.title}

Redeye Publicerad: 10 Jul 13:08

Redeye leaves its comments on Xspray following a press release confirming that XS003 shows matching bioavailability to Tasigna at a more than 50% lower dose.

Länk till analysen i sin helhet: https://www.redeye.se/research/1020521/xspray-pharma-additional-positive-xs003-data?utm_source=finwire&utm_medium=RSS

Nyheter om Xspray Pharma

Läses av andra just nu

Om aktien Xspray Pharma

Senaste nytt